Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $37.6 million versus the consensus estimate of $35.67 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of $150.3 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.